Vice President, Regulatory Affairs

Since joining the company in 2007, David’s responsibilities have included strategic regulatory planning, submission preparation and leading all interactions with key regulatory authorities including the US FDA and the European Medicines Agency.

During his 30-year career in the life sciences industry, David has specialized in the areas of regulatory and clinical affairs. He has held a series of leadership positions within Cordis Corporation (a Johnson & Johnson company) and was assigned regulatory responsibility for cardiovascular products following J&J’s acquisition of Cordis in 1996. While at Cordis, David was primarily responsible for securing market approval in US, EU and Japan for the CYPHER® Sirolimus-eluting Coronary Stent (the first drug-eluting coronary stent).

Prior to joining Vascular Therapies, he was Worldwide Director, Regulatory Affairs for cardiology drug-device combination products at two early stage device companies.

David holds a B.A. in Education from Queens College, CUNY, and an M.A., Ed.M. and Ed.D. in Movement Sciences and Education from Teachers College, Columbia University. He has authored publications on motor learning, neuroscience and regulatory affairs.